Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
65
BHC.TO Quote, Financials, Valuation and Earnings
Last price:
$9.49
Seasonality move
:
11.65%
Day range:
$9.38 - $9.73
52-week range:
$5.91 - $11.97
Dividend yield:
0%
P/E ratio:
7.11x
P/S ratio:
0.25x
P/B ratio:
--
Volume:
2.5M
Avg. volume:
468.7K
1-year change:
-10.81%
Market cap:
$3.5B
Revenue:
$13.2B
EPS (TTM):
$1.33
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BHC.TO
Bausch Health Cos., Inc.
|
$3.4B | $0.97 | 6.92% | 375.64% | $6.98 |
|
BLCO.TO
Bausch + Lomb Corp.
|
$1.7B | $0.10 | 6.36% | 1360.48% | $24.48 |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
TH.TO
Theratechnologies, Inc.
|
$30.9M | $0.07 | -6.56% | -91.8% | $7.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BHC.TO
Bausch Health Cos., Inc.
|
$9.49 | $6.98 | $3.5B | 7.11x | $0.00 | 0% | 0.25x |
|
BLCO.TO
Bausch + Lomb Corp.
|
$22.20 | $24.48 | $7.9B | -- | $0.00 | 0% | 1.13x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
TH.TO
Theratechnologies, Inc.
|
$4.47 | $7.25 | $205.5M | -- | $0.00 | 0% | 1.86x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BHC.TO
Bausch Health Cos., Inc.
|
102.76% | 0.758 | 636.35% | 0.78x |
|
BLCO.TO
Bausch + Lomb Corp.
|
43.5% | 2.067 | 91.5% | 0.76x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
TH.TO
Theratechnologies, Inc.
|
277.86% | -5.504 | 35.93% | 0.53x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BHC.TO
Bausch Health Cos., Inc.
|
$2.3B | $987.5M | 1.47% | -- | 26.74% | $433.6M |
|
BLCO.TO
Bausch + Lomb Corp.
|
$968.3M | $110.2M | -2.64% | -4.61% | 6.25% | $90.1M |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
TH.TO
Theratechnologies, Inc.
|
$18.2M | -$2.8M | -33.9% | -- | -11.28% | $17.8M |
Bausch Health Cos., Inc. vs. Competitors
-
Which has Higher Returns BHC.TO or BLCO.TO?
Bausch + Lomb Corp. has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of -1.95%. Bausch Health Cos., Inc.'s return on equity of -- beat Bausch + Lomb Corp.'s return on equity of -4.61%.
Company Gross Margin Earnings Per Share Invested Capital BHC.TOBausch Health Cos., Inc.62.59% $0.66 $29.8B BLCO.TOBausch + Lomb Corp.54.88% -$0.11 $15.9B -
What do Analysts Say About BHC.TO or BLCO.TO?
Bausch Health Cos., Inc. has a consensus price target of $6.98, signalling downside risk potential of -26.41%. On the other hand Bausch + Lomb Corp. has an analysts' consensus of $24.48 which suggests that it could grow by 10.26%. Given that Bausch + Lomb Corp. has higher upside potential than Bausch Health Cos., Inc., analysts believe Bausch + Lomb Corp. is more attractive than Bausch Health Cos., Inc..
Company Buy Ratings Hold Ratings Sell Ratings BHC.TOBausch Health Cos., Inc.0 7 0 BLCO.TOBausch + Lomb Corp.4 8 0 -
Is BHC.TO or BLCO.TO More Risky?
Bausch Health Cos., Inc. has a beta of 0.372, which suggesting that the stock is 62.787% less volatile than S&P 500. In comparison Bausch + Lomb Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BHC.TO or BLCO.TO?
Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bausch + Lomb Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. Bausch + Lomb Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHC.TO or BLCO.TO?
Bausch Health Cos., Inc. quarterly revenues are $3.7B, which are larger than Bausch + Lomb Corp. quarterly revenues of $1.8B. Bausch Health Cos., Inc.'s net income of $249.3M is higher than Bausch + Lomb Corp.'s net income of -$34.4M. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 7.11x while Bausch + Lomb Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.25x versus 1.13x for Bausch + Lomb Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHC.TOBausch Health Cos., Inc.0.25x 7.11x $3.7B $249.3M BLCO.TOBausch + Lomb Corp.1.13x -- $1.8B -$34.4M
-
Which has Higher Returns BHC.TO or COOL.CX?
Core One Labs, Inc. has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of --. Bausch Health Cos., Inc.'s return on equity of -- beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BHC.TOBausch Health Cos., Inc.62.59% $0.66 $29.8B COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About BHC.TO or COOL.CX?
Bausch Health Cos., Inc. has a consensus price target of $6.98, signalling downside risk potential of -26.41%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Bausch Health Cos., Inc. has higher upside potential than Core One Labs, Inc., analysts believe Bausch Health Cos., Inc. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BHC.TOBausch Health Cos., Inc.0 7 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is BHC.TO or COOL.CX More Risky?
Bausch Health Cos., Inc. has a beta of 0.372, which suggesting that the stock is 62.787% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock BHC.TO or COOL.CX?
Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHC.TO or COOL.CX?
Bausch Health Cos., Inc. quarterly revenues are $3.7B, which are larger than Core One Labs, Inc. quarterly revenues of --. Bausch Health Cos., Inc.'s net income of $249.3M is higher than Core One Labs, Inc.'s net income of --. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 7.11x while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.25x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHC.TOBausch Health Cos., Inc.0.25x 7.11x $3.7B $249.3M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns BHC.TO or CURE.X.CX?
Biocure Technology has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of --. Bausch Health Cos., Inc.'s return on equity of -- beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BHC.TOBausch Health Cos., Inc.62.59% $0.66 $29.8B CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About BHC.TO or CURE.X.CX?
Bausch Health Cos., Inc. has a consensus price target of $6.98, signalling downside risk potential of -26.41%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Bausch Health Cos., Inc. has higher upside potential than Biocure Technology, analysts believe Bausch Health Cos., Inc. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings BHC.TOBausch Health Cos., Inc.0 7 0 CURE.X.CXBiocure Technology0 0 0 -
Is BHC.TO or CURE.X.CX More Risky?
Bausch Health Cos., Inc. has a beta of 0.372, which suggesting that the stock is 62.787% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BHC.TO or CURE.X.CX?
Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHC.TO or CURE.X.CX?
Bausch Health Cos., Inc. quarterly revenues are $3.7B, which are larger than Biocure Technology quarterly revenues of --. Bausch Health Cos., Inc.'s net income of $249.3M is higher than Biocure Technology's net income of --. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 7.11x while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.25x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHC.TOBausch Health Cos., Inc.0.25x 7.11x $3.7B $249.3M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns BHC.TO or HEAL.CX?
has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of --. Bausch Health Cos., Inc.'s return on equity of -- beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BHC.TOBausch Health Cos., Inc.62.59% $0.66 $29.8B HEAL.CX-- -- -- -
What do Analysts Say About BHC.TO or HEAL.CX?
Bausch Health Cos., Inc. has a consensus price target of $6.98, signalling downside risk potential of -26.41%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Bausch Health Cos., Inc. has higher upside potential than , analysts believe Bausch Health Cos., Inc. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings BHC.TOBausch Health Cos., Inc.0 7 0 HEAL.CX0 0 0 -
Is BHC.TO or HEAL.CX More Risky?
Bausch Health Cos., Inc. has a beta of 0.372, which suggesting that the stock is 62.787% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BHC.TO or HEAL.CX?
Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHC.TO or HEAL.CX?
Bausch Health Cos., Inc. quarterly revenues are $3.7B, which are larger than quarterly revenues of --. Bausch Health Cos., Inc.'s net income of $249.3M is higher than 's net income of --. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 7.11x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.25x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHC.TOBausch Health Cos., Inc.0.25x 7.11x $3.7B $249.3M HEAL.CX-- -- -- --
-
Which has Higher Returns BHC.TO or TH.TO?
Theratechnologies, Inc. has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of -25.17%. Bausch Health Cos., Inc.'s return on equity of -- beat Theratechnologies, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BHC.TOBausch Health Cos., Inc.62.59% $0.66 $29.8B TH.TOTheratechnologies, Inc.72.86% -$0.13 $21.6M -
What do Analysts Say About BHC.TO or TH.TO?
Bausch Health Cos., Inc. has a consensus price target of $6.98, signalling downside risk potential of -26.41%. On the other hand Theratechnologies, Inc. has an analysts' consensus of $7.25 which suggests that it could grow by 62.19%. Given that Theratechnologies, Inc. has higher upside potential than Bausch Health Cos., Inc., analysts believe Theratechnologies, Inc. is more attractive than Bausch Health Cos., Inc..
Company Buy Ratings Hold Ratings Sell Ratings BHC.TOBausch Health Cos., Inc.0 7 0 TH.TOTheratechnologies, Inc.0 0 0 -
Is BHC.TO or TH.TO More Risky?
Bausch Health Cos., Inc. has a beta of 0.372, which suggesting that the stock is 62.787% less volatile than S&P 500. In comparison Theratechnologies, Inc. has a beta of 0.734, suggesting its less volatile than the S&P 500 by 26.573%.
-
Which is a Better Dividend Stock BHC.TO or TH.TO?
Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theratechnologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. Theratechnologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BHC.TO or TH.TO?
Bausch Health Cos., Inc. quarterly revenues are $3.7B, which are larger than Theratechnologies, Inc. quarterly revenues of $24.9M. Bausch Health Cos., Inc.'s net income of $249.3M is higher than Theratechnologies, Inc.'s net income of -$6.3M. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 7.11x while Theratechnologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.25x versus 1.86x for Theratechnologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BHC.TOBausch Health Cos., Inc.0.25x 7.11x $3.7B $249.3M TH.TOTheratechnologies, Inc.1.86x -- $24.9M -$6.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
